Chengdu Enduoshi Biological Engineering Technology

Chengdu Enduoshi Biological Engineering Technology is a biotechnology firm based in Chengdu, China, specializing in the field of gene therapy and recombinant protein engineering. The company was established by Dr. Peng Zhaohui, who is widely recognized for developing Gendicine, the world's first commercially licensed gene therapy product. Chengdu Enduoshi focuses on the research, development, and production of adenovirus-based therapies targeting the p53 tumor suppressor gene for various oncology indications. Its work encompasses the entire lifecycle of gene therapy products, from early-stage molecular research to large-scale GMP manufacturing. The company plays a significant role in the Chinese domestic biotech landscape, particularly in the application of viral vectors for cancer treatment. It continues to explore combination therapies involving its core p53 technology to improve outcomes in solid tumors.